All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @tetraquel on TikTok · 47s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @tetraquel's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Asempic is the latest get-then-quick drug that's doing the rounds on social media, but it's
  2. 0:05already causing a lot of problems.
  3. 0:07First of all, Asempic isn't a weight loss drug.
  4. 0:09It's a diabetes drug that regulates blood sugar and insulin, which happens to also make
  5. 0:14people feel full faster, causing them to lose weight quickly.
  6. 0:17And because celebrities and now ordinary people have cut onto this, there's now a worldwide
  7. 0:22shortage.
  8. 0:23The irony is, people who have taken Asempic for weight loss are already having regrets.
  9. 0:28As soon as it began going viral, so did the hashtag AsempicFace, referring to the gaunt
  10. 0:33aging effect that drastic weight loss can have on people.
  11. 0:36But really, this isn't people's fault or even social medias.
  12. 0:39It's whoever's been prescribing it.
  13. 0:42So everyone, let's leave this medication for the people whose life it's going to save.

@tetraquel's semaglutide claims, fact-checked

Tetraquel

TikTok creator

189.1K viewsWatch on TikTok

Quick answer

Semaglutide received two separate FDA approvals: as Ozempic (0.5mg-2mg) for type 2 diabetes in 2017, and as Wegovy (2.4mg weekly) for chronic weight management in adults with obesity or overweight with a weight-related condition in 2021. Weight loss via GLP-1 receptor agonism is a direct pharmacological mechanism involving hypothalamic satiety pathways, not an incidental side effect. The creator's framing that weight loss is accidental conflates the drug's original indication with its established, intentionally developed second indication.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @tetraquel's semaglutide claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@tetraquel's semaglutide claims, fact-checked" from Tetraquel. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide received two separate FDA approvals: as Ozempic (0.

The reason this review is not generic is the source wording and the canonical claim label "glp1 semiglutide was not developed for weight loss it is a side." In this clip, the useful excerpt is: "Asempic is the latest get-then-quick drug that's doing the rounds on social media, but it's already causing a lot of problems." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

In the STEP 1 trial (Wilding et al.
People who land here are usually trying to understand whether the Compounded Semaglutide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide received two separate FDA approvals: as Ozempic (0.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide received two separate FDA approvals: as Ozempic (0.5mg-2mg) for type 2 diabetes in 2017, and as Wegovy (2.4mg weekly) for chronic weight management in adults with obesity or overweight with a weight-related condition in 2021. Weight loss via GLP-1 receptor agonism is a direct pharmacological mechanism involving hypothalamic satiety pathways, not an incidental side effect. The creator's framing that weight loss is accidental conflates the drug's original indication with its established, intentionally developed second indication.
  • Semaglutide received a dedicated FDA approval for chronic weight management as Wegovy in 2021, separate from its diabetes indication, making the 'accidental side effect' framing inaccurate.
  • In the STEP 1 trial (Wilding et al., 2021, NEJM), semaglutide 2.4mg produced an average 14.9% body weight reduction versus 2.4% for placebo in adults without diabetes.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Semaglutide received a dedicated FDA approval for chronic weight management as Wegovy in 2021, separate from its diabetes indication, making the 'accidental side effect' framing inaccurate.
  • In the STEP 1 trial (Wilding et al., 2021, NEJM), semaglutide 2.4mg produced an average 14.9% body weight reduction versus 2.4% for placebo in adults without diabetes.
  • The SELECT cardiovascular outcomes trial (Lincoff et al., 2023, NEJM) found semaglutide reduced major cardiovascular events by 20% in overweight or obese adults without diabetes, countering the claim that non-diabetic use is purely cosmetic.
  • Ozempic Face is a colloquial term for facial fat loss with rapid weight reduction; it is not a classified adverse drug reaction and can occur with any significant caloric deficit.
  • The FDA has flagged hundreds of weight loss supplements for containing undisclosed stimulants, diuretics, or controlled substances; supplements like RapidSlim face no pre-market efficacy or safety requirements.
  • Semaglutide does carry real documented risks including gastrointestinal side effects in a majority of users, a pancreatitis risk, and a black box warning for thyroid C-cell tumors based on rodent data, all of which should be discussed with a clinician.
  • No published clinical trial compares RapidSlim directly to semaglutide; the caption claim that it delivers better results is an unsupported comparative efficacy claim with no regulatory or scientific basis.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @tetraquel actually say?

The creator made several claims about semaglutide (which they called "Asempic," a mispronunciation of Ozempic). Their core argument: it is "a diabetes drug that regulates blood sugar and insulin, which happens to also make people feel full faster" and that weight loss is essentially an accidental benefit. They also pointed to "Ozempic Face" as evidence of harm, blamed prescribers for misuse, and ended with a call to reserve the medication for diabetic patients. The video caption, separately, promotes a product called RapidSlim as a proven, safer alternative. That promotional claim is not supported by any clinical evidence and is a red flag we will get to.

Does the science back this up?

Partially, yes, but the framing is sloppy in ways that matter. Semaglutide was originally approved by the FDA in 2017 for type 2 diabetes (as Ozempic). However, the idea that weight loss is simply a "side effect" misrepresents how GLP-1 receptor agonists actually work. The drug acts on GLP-1 receptors in the brain, gut, and pancreas. Satiety signaling in the hypothalamus is a direct pharmacological mechanism, not an accidental byproduct.

In the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), participants without diabetes lost an average of 14.9% of body weight on semaglutide 2.4mg versus 2.4% on placebo. That trial was the basis for Wegovy's 2021 FDA approval specifically for chronic weight management. Wegovy and Ozempic contain the same molecule at different doses, developed intentionally for different indications. Calling weight loss a side effect ignores that regulatory history entirely.

What did they get wrong, and what did they get right?

They got the shortage point right. The FDA did list semaglutide injection on its drug shortage list, and compounding pharmacies stepped in to fill demand, raising their own set of safety and regulatory questions.

They got "Ozempic Face" partly right in the sense that rapid fat loss, particularly facial fat, is a real aesthetic concern some patients report. But framing it as a dangerous side effect of the drug itself is misleading. It is a consequence of rapid weight loss from any cause, not a pharmacological toxicity. No peer-reviewed literature classifies it as a medical harm.

What they got wrong is consequential. The video caption claims RapidSlim is "proven to give better results" than semaglutide injections. There is no published clinical trial evidence for RapidSlim outperforming a GLP-1 receptor agonist on weight loss outcomes. This is an unverifiable marketing claim attached to a video designed to generate fear about a regulated medication. That is worth naming directly.

What should you actually know?

Semaglutide is not risk-free. Real documented side effects include nausea, vomiting, diarrhea, and constipation, which are common, and rarer but more serious risks including pancreatitis and a black box warning for thyroid C-cell tumors in rodent studies (clinical significance in humans remains under study). The FDA label is transparent about this.

But the creator's implicit suggestion, that avoiding semaglutide in favor of an unregulated supplement is the safer choice, is not supported by evidence. Supplements marketed for weight loss are not required to demonstrate safety or efficacy before going to market. The FDA has issued hundreds of warnings about weight loss supplements containing undisclosed stimulants, laxatives, or controlled substances (FDA, 2024, tainted products database).

If you are considering semaglutide for weight management, that conversation belongs with a licensed clinician who can review your history, not a TikTok video promoting a competing product.

What about the promotional claim in the caption?

The caption directly states RapidSlim is "proven to give better results" than semaglutide injections. This is a comparative efficacy claim. For that to be true, RapidSlim would need to have been tested in a randomized controlled trial against semaglutide. No such trial exists in peer-reviewed literature. This type of claim, attaching fear-based content about a regulated drug to a competing unverified product, is a common influencer marketing pattern. Viewers should treat it accordingly.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Tetraquel · TikTok creator

189.1K views on this video

Semiglutide was not developed for weight loss, it is a side effect of it. But did you know of the other dangerous side effects? Don't risk your health on harmful injections when RapidSlim is proven to

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide received a dedicated fda approval for chronic weight management?

Semaglutide received a dedicated FDA approval for chronic weight management as Wegovy in 2021, separate from its diabetes indication, making the 'accidental side effect' framing inaccurate.

What does the video say about in the step 1 trial (wilding et al., 2021, nejm),?

In the STEP 1 trial (Wilding et al., 2021, NEJM), semaglutide 2.4mg produced an average 14.9% body weight reduction versus 2.4% for placebo in adults without diabetes.

What does the video say about the select cardiovascular outcomes trial (lincoff et al., 2023, nejm)?

The SELECT cardiovascular outcomes trial (Lincoff et al., 2023, NEJM) found semaglutide reduced major cardiovascular events by 20% in overweight or obese adults without diabetes, countering the claim that non-diabetic use is purely cosmetic.

What does the video say about ozempic face?

Ozempic Face is a colloquial term for facial fat loss with rapid weight reduction; it is not a classified adverse drug reaction and can occur with any significant caloric deficit.

What does the video say about the fda has flagged hundreds of weight loss supplements for?

The FDA has flagged hundreds of weight loss supplements for containing undisclosed stimulants, diuretics, or controlled substances; supplements like RapidSlim face no pre-market efficacy or safety requirements.

What does the video say about semaglutide does carry real documented risks including gastrointestinal side effects?

Semaglutide does carry real documented risks including gastrointestinal side effects in a majority of users, a pancreatitis risk, and a black box warning for thyroid C-cell tumors based on rodent data, all of which should be discussed with a clinician.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Tetraquel, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.